News and stories from the WVU Eye Institute
WVU Eye Institute retinopathy of prematurity clinical trial results in FDA approval
A clinical trial conducted by the WVU Eye Institute for the use of EYELEA, an injection medication, has led to FDA approval for the treatment of retinopathy of prematurity (ROP).
Peter Stoilov and Visvanathan Ramamurthy—researchers at the West Virginia University School of Medicine—have spent the last several years collaborating to study proteins called Musashi, the loss of which causes rapid retinal degeneration. Their project recently received its fifth year of funding—$502,444—from the National Eye Institute, a division of the National Institutes of Health.
WVU Eye Institute offering corneal neurotization
The WVU Eye Institute is the first in the region to offer corneal neurotization, a surgery that reconnects nerves to the eye in order to restore sensation.
With a new $11 million grant from the National Institutes of Health, West Virginia University has become just the second university in the country to receive funding for a visual-sciences Center of Biomedical Research Excellence.
In the news
WV News I May 26, 2021
Nationally Recognized. Unrivaled Expertise and Care.
Tuesday Talks: Thyroid Eye Disease